<?xml version="1.0" encoding="UTF-8"?>
<GoldLabel drug="DEXAMETHASONE">
  <Text>
    <Section id="S1" name="adverse reactions">  ADVERSE REACTIONS

    (Listed alphabetically, under each subsection)  

 The following adverse reactions have been reported with dexamethasone or other corticosteroids:

   Allergic Reactions

  Anaphylactoid reaction, anaphylaxis, angioedema.

   Cardiovascular

  Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction (see    WARNINGS  :  Cardio-Renal    ), edema, pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis.

   Dermatologic

  Acne, allergic dermatitis, dry scaly skin, ecchymoses and petechiae, erythema, impaired wound healing, increased sweating, rash, striae, suppression of reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria.

   Endocrine

  Decreased carbohydrate and glucose tolerance, development of cushingoid state, hyperglycemia, glycosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic agents in diabetes, manifestations of latent diabetes mellitus, menstrual irregularities, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery, or illness), suppression of growth in pediatric patients.

   Fluid and Electrolyte Disturbances

  Congestive heart failure in susceptible patients, fluid retention, hypokalemic alkalosis, potassium loss, sodium retention.

   Gastrointestinal

  Abdominal distention, elevation in serum liver enzyme levels (usually reversible upon discontinuation), hepatomegaly, increased appetite, nausea, pancreatitis, peptic ulcer with possible perforation and hemorrhage, perforation of the small and large intestine (particularly in patients with inflammatory bowel disease), ulcerative esophagitis.

   Metabolic

  Negative nitrogen balance due to protein catabolism.

   Musculoskeletal

  Aseptic necrosis of femoral and humeral heads, loss of muscle mass, muscle weakness, osteoporosis, pathologic fracture of long bones, steroid myopathy, tendon rupture, vertebral compression fractures.

   Neurological/Psychiatric

  Convulsions, depression, emotional instability, euphoria, headache, increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment, insomnia, mood swings, neuritis, neuropathy, paresthesia, personality changes, psychic disorders, vertigo.

   Ophthalmic

  Exophthalmos, glaucoma, increased intraocular pressure, posterior subcapsular cataracts.

   Other

  Abnormal fat deposits, decreased resistance to infection, hiccups, increased or decreased motility and number of spermatozoa, malaise, moon face, weight gain.

</Section>
    <Section id="S2" name="precautions">   PRECAUTIONS

   General

  The lowest possible dose of corticosteroids should be used to control the condition under treatment. When reduction in dosage is possible, the reduction should be gradual.

 Since complications of treatment with corticosteroids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.

 Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement.

    Cardio-Renal

  As sodium retention with resultant edema and potassium loss may occur in patients receiving corticosteroids, these agents should be used with caution in patients with congestive heart failure, hypertension, or renal insufficiency

    Endocrine

  Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.

    Gastrointestinal

  Steroids should be used with caution in active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and nonspecific ulcerative colitis, since they may increase the risk of a perforation.

 Signs of peritoneal irritation following gastrointestinal perforation in patients receiving corticosteroids may be minimal or absent.

 There is an enhanced effect due to decreased metabolism of corticosteroids in patients with cirrhosis.

    Musculoskeletal

  Corticosteroids decrease bone formation and increase bone resorption both through their effect on calcium regulation (i.e., decreasing absorption and increasing excretion) and inhibition of osteoblast function. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of bone growth in pediatric patients and the development of osteoporosis at any age. Special consideration should be given to patients at increased risk of osteoporosis (e.g., postmenopausal women) before initiating corticosteroid therapy.

    Neuro-Psychiatric

  Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that they affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect (see   DOSAGE AND ADMINISTRATION    ).

 An acute myopathy has been observed with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g., myasthenia gravis), or in patients receiving concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium). This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis. Elevation of creatinine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.

 Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.

    Ophthalmic

  lntraocular pressure may become elevated in some individuals. If steroid therapy is continued for more than 6 weeks, intraocular pressure should be monitored.

    Information for Patients

  Patients should be warned not to discontinue the use of corticosteroids abruptly or without medical supervision. As prolonged use may cause adrenal insufficiency and make patients dependent on corticosteroids, they should advise any medical attendants that they are taking corticosteroids and they should seek medical advice at once should they develop an acute illness including fever or other signs of infection. Following prolonged therapy, withdrawal of corticosteroids may result in symptoms of the corticosteroid withdrawal syndrome including, myalgia, arthralgia, and malaise.

 Persons who are on corticosteroids should be warned to avoid exposure to chickenpox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay.

    Drug Interactions

   Aminoglutethimide  : Aminoglutethimide may diminish adrenal suppression by corticosteroids.

  Amphotericin B Injection and Potassium-depleting agents  : When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.

  Antibiotics  : Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see Drug Interactions: Hepatic Enzyme Inducers, Inhibitors and Substrates).

  Anticholinesterases  : Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.

  Anticoagulants, Oral  : Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect.

  Antidiabetics  : Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.

  Antitubercular Drugs  : Serum concentrations of isoniazid may be decreased.

  Cholestyramine  : Cholestyramine may increase the clearance of corticosteroids.

  Cyclosporine  : Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use.

  Dexamethasone Suppression Test (DST)  : False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients.

  Digitalis Glycosides  : Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia.

  Ephedrine  : Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.

  Estrogens, Including Oral Contraceptives  : Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.

  Hepatic Enzyme Inducers, Inhibitors and Substrates  : Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity ( e.g., barbiturates, phenytoin, carbamazepine, rifampin  ) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Drugs which inhibit CYP 3A4 ( e.g., ketoconazole, macrolide antibiotics such as erythromycin  ) have the potential to result in increased plasma concentrations of corticosteroids. Dexamethasone is a moderate inducer of CYP 3A4. Co-adminstration with other drugs that are metabolized by CYP 3A4 ( e.g., indinavir, erythromycin  ) may increase their clearance, resulting in decreased plasma concentration.

  Ketoconazole  : Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects. In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.

  Nonsteroidal Anti-Inflammatory Agents (NSAIDS)  : Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids.

  Phenytoin  : In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.

  Skin Tests  : Corticosteroids may suppress reactions to skin tests.

  Thalidomide  : Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use.

  Vaccines  : Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see   WARNINGS  :  Infections  :  Vaccination    ).

    Carcinogenesis, Mutagenesis, Impairment of Fertility

  No adequate studies have been conducted in animals to determine whether corticosteroids have a potential for carcinogenesis or mutagenesis.

 Steroids may increase or decrease motility and number of spermatozoa in some patients.

    Pregnancy

   Teratogenic Effects: Pregnancy Category C    : Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to the human dose. Animal studies in which corticosteroids have been given to pregnant mice, rats, and rabbits have yielded an increased incidence of cleft palate in the offspring. There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism.

    Nursing Mothers

  Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants from corticosteroids, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

    Pediatric Use

  The efficacy and safety of corticosteroids in the pediatric population are based on the well-established course of effect of corticosteroids, which is similar in pediatric and adult populations. Published studies provide evidence of efficacy and safety in pediatric patients for the treatment of nephrotic syndrome (patients &gt;2 years of age), and aggressive lymphomas and leukemias (patients &gt;1 month of age). Other indications for pediatric use of corticosteroids, e.g., severe asthma and wheezing, are based on adequate and well-controlled trials conducted in adults, on the premises that the course of the diseases and their pathophysiology are considered to be substantially similar in both populations.

 The adverse effects of corticosteroids in pediatric patients are similar to those in adults (see   ADVERSE REACTIONS    ). Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of infection, psychosocial disturbances, thromboembolism, peptic ulcers, cataracts, and osteoporosis. Pediatric patients who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity. This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression (i.e., cosyntropin stimulation and basal cortisol plasma levels). Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. The linear growth of pediatric patients treated with corticosteroids should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of treatment alternatives. In order to minimize the potential growth effects of corticosteroids, pediatric patients should be titrated  to the lowest effective dose.

    Geriatric Use

  Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. In particular, the increased risk of diabetes mellitus, fluid retention and hypertension in elderly patients treated with corticosteroids should be considered.

</Section>
    <Section id="S3" name="warnings">   WARNINGS

   General

  Rare instances of anaphylactoid reactions have occurred in patients receiving corticosteroid therapy (see   ADVERSE REACTIONS    ).

 Increased dosage of rapidly acting corticosteroids is indicated in patients on corticosteroid therapy subjected to any unusual stress before, during, and after the stressful situation.

    Cardio-Renal

  Average and large doses of corticosteroids can cause elevation of blood pressure, sodium and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.

 Literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent myocardial infarction; therefore, therapy with corticosteroids should be used with great caution in these patients.

    Endocrine

  Corticosteroids can produce reversible hypothalamic-pituitary adrenal (HPA) axis suppression with the potential for corticosteroid insufficiency after withdrawal of treatment. Adrenocortical insufficiency may result from too rapid withdrawal of corticosteroids and may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. If the patient is receiving steroids already, dosage may have to be increased.

 Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients. Changes in thyroid status of the patient may necessitate adjustment in dosage.

    Infections

   General  

 Patients who are on corticosteroids are more susceptible to infections than are healthy individuals. There may be decreased resistance and inability to localize infection when corticosteroids are used. Infection with any pathogen (viral, bacterial, fungal, protozoan or helminthic) in any location of the body may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents. These infections may be mild to severe. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. Corticosteroids may also mask some signs of current infection.

  Fungal Infections  :Corticosteroids may exacerbate systemic fungal infections and therefore should not be used in the presence of such infections unless they are needed to control life-threatening drug reactions. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure (see   PRECAUTIONS  :  Drug Interactions  :  Amphotericin B injection and potassium-depleting agents    ).

  Special Pathogens  : Latent disease may be activated or there may be an exacerbation of intercurrent infections due to pathogens, including those caused by Amoeba  , Candida  , Cryptococcus  , Mycobacterium  , Nocardia  , Pneumocystis  , Toxoplasma  .

 It is recommended that latent amebiasis or active amebiasis be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or any patient with unexplained diarrhea.

 Similarly, corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.

 Corticosteroids should not be used in cerebral malaria.

  Tuberculosis  : The use of corticosteroids in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.

 If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.

  Vaccination  : Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered. However, the response to such vaccines cannot be predicted.  Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison's disease.

  Viral Infections  : Chickenpox and measles can have a more serious or even fatal course in pediatric and adult patients on corticosteroids. In pediatric and adult patients who have not had these diseases, particular care should be taken to avoid exposure. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chickenpox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with immune globulin (IG) may be indicated. (See the respective package inserts for VZIG and IG for complete prescribing information.) If chickenpox develops, treatment with antiviral agents should be considered.

    Ophthalmic

  Use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. The use of oral corticosteroids is not recommended in the treatment of optic neuritis and may lead to an increase in the risk of new episodes. Corticosteroids should not be used in active ocular herpes simplex.

</Section>
  </Text>
  <IgnoredRegions>
    <IgnoredRegion len="17" name="heading" section="S1" start="2" />
    <IgnoredRegion len="11" name="heading" section="S2" start="3" />
    <IgnoredRegion len="8" name="heading" section="S3" start="3" />
    <IgnoredRegion len="7" name="heading" section="S3" start="16" />
    <IgnoredRegion len="7" name="heading" section="S2" start="19" />
    <IgnoredRegion len="18" name="heading" section="S1" start="176" />
    <IgnoredRegion len="14" name="heading" section="S1" start="251" />
    <IgnoredRegion len="12" name="heading" section="S3" start="351" />
    <IgnoredRegion len="12" name="heading" section="S1" start="661" />
    <IgnoredRegion len="12" name="heading" section="S2" start="692" />
    <IgnoredRegion len="9" name="heading" section="S1" start="909" />
    <IgnoredRegion len="9" name="heading" section="S2" start="943" />
    <IgnoredRegion len="9" name="heading" section="S3" start="998" />
    <IgnoredRegion len="34" name="heading" section="S1" start="1376" />
    <IgnoredRegion len="16" name="heading" section="S2" start="1383" />
    <IgnoredRegion len="16" name="heading" section="S1" start="1542" />
    <IgnoredRegion len="10" name="heading" section="S3" start="1807" />
    <IgnoredRegion len="15" name="heading" section="S2" start="1854" />
    <IgnoredRegion len="9" name="heading" section="S1" start="1910" />
    <IgnoredRegion len="15" name="heading" section="S1" start="1980" />
    <IgnoredRegion len="24" name="heading" section="S1" start="2204" />
    <IgnoredRegion len="17" name="heading" section="S2" start="2501" />
    <IgnoredRegion len="10" name="heading" section="S1" start="2530" />
    <IgnoredRegion len="5" name="heading" section="S1" start="2637" />
    <IgnoredRegion len="10" name="heading" section="S2" start="3750" />
    <IgnoredRegion len="24" name="heading" section="S2" start="3928" />
    <IgnoredRegion len="17" name="heading" section="S2" start="4748" />
    <IgnoredRegion len="10" name="heading" section="S3" start="5514" />
    <IgnoredRegion len="52" name="heading" section="S2" start="9552" />
    <IgnoredRegion len="9" name="heading" section="S2" start="9842" />
    <IgnoredRegion len="15" name="heading" section="S2" start="10530" />
    <IgnoredRegion len="13" name="heading" section="S2" start="10973" />
    <IgnoredRegion len="13" name="heading" section="S2" start="13102" />
  </IgnoredRegions>
  <Mentions>
    <Mention id="M6" len="22" reason="from_drug_use" section="S1" start="198" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anaphylactoid reaction" meddra_llt_id="10002216" meddra_pt="Anaphylactoid reaction" meddra_pt_id="10002216" />
    </Mention>
    <Mention id="M7" len="11" reason="from_drug_use" section="S1" start="222" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anaphylaxis" meddra_llt_id="10002218" meddra_pt="Anaphylactic reaction" meddra_pt_id="10002198" />
    </Mention>
    <Mention id="M8" len="10" reason="from_drug_use" section="S1" start="235" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Angioedema" meddra_llt_id="10002424" meddra_pt="Angioedema" meddra_pt_id="10002424" />
    </Mention>
    <Mention id="M9" len="11" reason="from_drug_use" section="S1" start="269" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bradycardia" meddra_llt_id="10006093" meddra_pt="Bradycardia" meddra_pt_id="10006093" />
    </Mention>
    <Mention id="M10" len="14" reason="from_drug_use" section="S1" start="282" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Arrest cardiac" meddra_llt_id="10003109" meddra_pt="Cardiac arrest" meddra_pt_id="10007515" />
    </Mention>
    <Mention id="M11" len="19" reason="from_drug_use" section="S1" start="298" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cardiac arrhythmia" meddra_llt_id="10007518" meddra_pt="Arrhythmia" meddra_pt_id="10003119" />
    </Mention>
    <Mention id="M12" len="19" reason="from_drug_use" section="S1" start="319" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Enlargement heart" meddra_llt_id="10014846" meddra_pt="Cardiomegaly" meddra_pt_id="10007632" />
    </Mention>
    <Mention id="M13" len="20" reason="from_drug_use" section="S1" start="340" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Collapse circulatory" meddra_llt_id="10009909" meddra_pt="Circulatory collapse" meddra_pt_id="10009192" />
    </Mention>
    <Mention id="M14" len="24" reason="from_drug_use" section="S1" start="362" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Congestive heart failure" meddra_llt_id="10010684" meddra_pt="Cardiac failure congestive" meddra_pt_id="10007559" />
    </Mention>
    <Mention id="M15" len="12" reason="from_drug_use" section="S1" start="388" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fat embolism" meddra_llt_id="10016246" meddra_pt="Fat embolism" meddra_pt_id="10016246" />
    </Mention>
    <Mention id="M16" len="12" reason="from_drug_use" section="S1" start="402" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M17" len="48" reason="from_drug_use" section="S1" start="416" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertrophic cardiomyopathy" meddra_llt_id="10020871" meddra_pt="Hypertrophic cardiomyopathy" meddra_pt_id="10020871" />
    </Mention>
    <Mention id="M18" len="18" reason="from_drug_use" section="S1" start="466" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myocardial rupture" meddra_llt_id="10028604" meddra_pt="Myocardial rupture" meddra_pt_id="10028604" />
    </Mention>
    <Mention id="M1" len="21" reason="preexisting_condition_or_risk_factor" section="S1" start="502" type="Not_AE_Candidate">
      <Normalization meddra_llt="Myocardial infarction" meddra_llt_id="10028596" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M19" len="5" reason="from_drug_use" section="S1" start="564" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Edema" meddra_llt_id="10014210" meddra_pt="Oedema" meddra_pt_id="10030095" />
    </Mention>
    <Mention id="M20" len="15" reason="from_drug_use" section="S1" start="571" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pulmonary edema" meddra_llt_id="10037375" meddra_pt="Pulmonary oedema" meddra_pt_id="10037423" />
    </Mention>
    <Mention id="M21" len="7" reason="from_drug_use" section="S1" start="588" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Syncope" meddra_llt_id="10042772" meddra_pt="Syncope" meddra_pt_id="10042772" />
    </Mention>
    <Mention id="M22" len="11" reason="from_drug_use" section="S1" start="597" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tachycardia" meddra_llt_id="10043071" meddra_pt="Tachycardia" meddra_pt_id="10043071" />
    </Mention>
    <Mention id="M23" len="15" reason="from_drug_use" section="S1" start="610" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thromboembolism" meddra_llt_id="10043566" meddra_pt="Embolism" meddra_pt_id="10061169" />
    </Mention>
    <Mention id="M24" len="16" reason="from_drug_use" section="S1" start="627" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombophlebitis" meddra_llt_id="10043570" meddra_pt="Thrombophlebitis" meddra_pt_id="10043570" />
    </Mention>
    <Mention id="M25" len="10" reason="from_drug_use" section="S1" start="645" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vasculitis" meddra_llt_id="10047115" meddra_pt="Vasculitis" meddra_pt_id="10047115" />
    </Mention>
    <Mention id="M110" len="4" reason="from_drug_use" section="S1" start="677" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Acne" meddra_llt_id="10000496" meddra_pt="Acne" meddra_pt_id="10000496" />
    </Mention>
    <Mention id="M26" len="19" reason="from_drug_use" section="S1" start="683" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Allergic dermatitis" meddra_llt_id="10001711" meddra_pt="Dermatitis allergic" meddra_pt_id="10012434" />
    </Mention>
    <Mention id="M27" len="3,4" reason="from_drug_use" section="S1" start="704,714" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry skin" meddra_llt_id="10013786" meddra_pt="Dry skin" meddra_pt_id="10013786" />
    </Mention>
    <Mention id="M106" len="10" reason="from_drug_use" section="S1" start="708" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Skin scaly" meddra_llt_id="10040920" meddra_pt="Skin exfoliation" meddra_pt_id="10040844" />
    </Mention>
    <Mention id="M28" len="10" reason="from_drug_use" section="S1" start="720" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ecchymoses" meddra_llt_id="10014079" meddra_pt="Ecchymosis" meddra_pt_id="10014080" />
    </Mention>
    <Mention id="M29" len="9" reason="from_drug_use" section="S1" start="735" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Petechiae" meddra_llt_id="10034754" meddra_pt="Petechiae" meddra_pt_id="10034754" />
    </Mention>
    <Mention id="M30" len="8" reason="from_drug_use" section="S1" start="746" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Erythema" meddra_llt_id="10015150" meddra_pt="Erythema" meddra_pt_id="10015150" />
    </Mention>
    <Mention id="M31" len="22" reason="from_drug_use" section="S1" start="756" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Healing impaired" meddra_llt_id="10019239" meddra_pt="Impaired healing" meddra_pt_id="10021519" />
    </Mention>
    <Mention id="M32" len="18" reason="from_drug_use" section="S1" start="780" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sweating increased" meddra_llt_id="10042667" meddra_pt="Hyperhidrosis" meddra_pt_id="10020642" />
    </Mention>
    <Mention id="M33" len="4" reason="from_drug_use" section="S1" start="800" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M34" len="6" reason="from_drug_use" section="S1" start="806" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Striae" meddra_llt_id="10042223" meddra_pt="Skin striae" meddra_pt_id="10040925" />
    </Mention>
    <Mention id="M35" len="38" reason="from_drug_use" section="S1" start="814" type="OSE_Labeled_AE">
      <Normalization meddra_llt="False negative investigation result" meddra_llt_id="10070747" meddra_pt="False negative investigation result" meddra_pt_id="10070747" />
    </Mention>
    <Mention id="M36" len="17" reason="from_drug_use" section="S1" start="854" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Atrophy skin" meddra_llt_id="10003719" meddra_pt="Skin atrophy" meddra_pt_id="10040799" />
    </Mention>
    <Mention id="M37" len="19" reason="from_drug_use" section="S1" start="873" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hair thinning" meddra_llt_id="10019050" meddra_pt="Alopecia" meddra_pt_id="10001760" />
    </Mention>
    <Mention id="M38" len="9" reason="from_drug_use" section="S1" start="894" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Urticaria" meddra_llt_id="10046735" meddra_pt="Urticaria" meddra_pt_id="10046735" />
    </Mention>
    <Mention id="M39" len="22,9" reason="from_drug_use" section="S1" start="922,957" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Carbohydrate tolerance decreased" meddra_llt_id="10007218" meddra_pt="Carbohydrate tolerance decreased" meddra_pt_id="10007218" />
    </Mention>
    <Mention id="M40" len="9,17" reason="from_drug_use" section="S1" start="922,949" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tolerance glucose decreased" meddra_llt_id="10043931" meddra_pt="Glucose tolerance decreased" meddra_pt_id="10018428" />
    </Mention>
    <Mention id="M41" len="16" reason="from_drug_use" section="S1" start="983" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cushingoid" meddra_llt_id="10011655" meddra_pt="Cushingoid" meddra_pt_id="10011655" />
    </Mention>
    <Mention id="M42" len="13" reason="from_drug_use" section="S1" start="1001" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperglycemia" meddra_llt_id="10020639" meddra_pt="Hyperglycaemia" meddra_pt_id="10020635" />
    </Mention>
    <Mention id="M43" len="10" reason="from_drug_use" section="S1" start="1016" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Glycosuria" meddra_llt_id="10018473" meddra_pt="Glycosuria" meddra_pt_id="10018473" />
    </Mention>
    <Mention id="M44" len="9" reason="from_drug_use" section="S1" start="1028" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hirsutism" meddra_llt_id="10020112" meddra_pt="Hirsutism" meddra_pt_id="10020112" />
    </Mention>
    <Mention id="M45" len="14" reason="from_drug_use" section="S1" start="1039" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertrichosis" meddra_llt_id="10020864" meddra_pt="Hypertrichosis" meddra_pt_id="10020864" />
    </Mention>
    <Mention id="M104" len="34,11" reason="from_drug_use" section="S1" start="1055,1118" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Increased insulin requirement" meddra_llt_id="10021664" meddra_pt="Increased insulin requirement" meddra_pt_id="10021664" />
    </Mention>
    <Mention id="M105" len="26,36" reason="from_drug_use" section="S1" start="1055,1093" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diabetes mellitus inadequate control" meddra_llt_id="10012607" meddra_pt="Diabetes mellitus inadequate control" meddra_pt_id="10012607" />
    </Mention>
    <Mention id="M46" len="24" reason="from_drug_use" section="S1" start="1149" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Latent diabetes" meddra_llt_id="10024016" meddra_pt="Glucose tolerance impaired" meddra_pt_id="10018429" />
    </Mention>
    <Mention id="M47" len="24" reason="from_drug_use" section="S1" start="1175" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Menstrual irregularity" meddra_llt_id="10027333" meddra_pt="Menstruation irregular" meddra_pt_id="10027339" />
    </Mention>
    <Mention id="M48" len="24,16" reason="from_drug_use" section="S1" start="1201,1240" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Secondary adrenocortical insufficiency" meddra_llt_id="10039807" meddra_pt="Secondary adrenocortical insufficiency" meddra_pt_id="10039807" />
    </Mention>
    <Mention id="M109" len="9,26" reason="from_drug_use" section="S1" start="1201,1230" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pituitary hypothyroidism" meddra_llt_id="10049517" meddra_pt="Secondary hypothyroidism" meddra_pt_id="10039840" />
    </Mention>
    <Mention id="M2" len="6" reason="preexisting_condition_or_risk_factor" section="S1" start="1283" type="Not_AE_Candidate">
      <Normalization meddra_llt="Stress" meddra_llt_id="10042209" meddra_pt="Stress" meddra_pt_id="10042209" />
    </Mention>
    <Mention id="M3" len="7" reason="preexisting_condition_or_risk_factor" section="S1" start="1317" type="Not_AE_Candidate">
      <Normalization meddra_llt="Illness" meddra_llt_id="10080284" meddra_pt="Ill-defined disorder" meddra_pt_id="10061520" />
    </Mention>
    <Mention id="M49" len="43" reason="from_drug_use" section="S1" start="1327" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Growth suppression" meddra_llt_id="10018761" meddra_pt="Growth retardation" meddra_pt_id="10053759" />
    </Mention>
    <Mention id="M50" len="24" reason="from_drug_use" section="S1" start="1414" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Congestive heart failure" meddra_llt_id="10010684" meddra_pt="Cardiac failure congestive" meddra_pt_id="10007559" />
    </Mention>
    <Mention id="M51" len="15" reason="from_drug_use" section="S1" start="1464" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fluid retention" meddra_llt_id="10016807" meddra_pt="Fluid retention" meddra_pt_id="10016807" />
    </Mention>
    <Mention id="M52" len="21" reason="from_drug_use" section="S1" start="1481" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Alkalosis hypokalemic" meddra_llt_id="10001685" meddra_pt="Alkalosis hypokalaemic" meddra_pt_id="10001684" />
    </Mention>
    <Mention id="M53" len="14" reason="from_drug_use" section="S1" start="1504" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypokalemia" meddra_llt_id="10021018" meddra_pt="Hypokalaemia" meddra_pt_id="10021015" />
      <Normalization meddra_pt="Blood potassium decreased" meddra_pt_id="10005724" />
    </Mention>
    <Mention id="M54" len="16" reason="from_drug_use" section="S1" start="1520" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sodium retention" meddra_llt_id="10041277" meddra_pt="Sodium retention" meddra_pt_id="10041277" />
    </Mention>
    <Mention id="M55" len="20" reason="from_drug_use" section="S1" start="1562" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Distention" meddra_llt_id="10013482" meddra_pt="Abdominal distension" meddra_pt_id="10000060" />
    </Mention>
    <Mention id="M56" len="38" reason="from_drug_use" section="S1" start="1584" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Elevated liver enzyme levels" meddra_llt_id="10014480" meddra_pt="Hepatic enzyme increased" meddra_pt_id="10060795" />
    </Mention>
    <Mention id="M57" len="12" reason="from_drug_use" section="S1" start="1666" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hepatomegaly" meddra_llt_id="10019842" meddra_pt="Hepatomegaly" meddra_pt_id="10019842" />
    </Mention>
    <Mention id="M58" len="18" reason="from_drug_use" section="S1" start="1680" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Increased appetite" meddra_llt_id="10021654" meddra_pt="Increased appetite" meddra_pt_id="10021654" />
    </Mention>
    <Mention id="M59" len="6" reason="from_drug_use" section="S1" start="1700" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M60" len="12" reason="from_drug_use" section="S1" start="1708" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pancreatitis" meddra_llt_id="10033645" meddra_pt="Pancreatitis" meddra_pt_id="10033645" />
    </Mention>
    <Mention id="M61" len="12" reason="from_drug_use" section="S1" start="1722" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Peptic ulcer" meddra_llt_id="10034341" meddra_pt="Peptic ulcer" meddra_pt_id="10034341" />
    </Mention>
    <Mention id="M62" len="12,11" reason="from_drug_use" section="S1" start="1722,1749" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Peptic ulcer perforation" meddra_llt_id="10034354" meddra_pt="Peptic ulcer perforation" meddra_pt_id="10034354" />
    </Mention>
    <Mention id="M63" len="12,10" reason="from_drug_use" section="S1" start="1722,1765" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Peptic ulcer hemorrhage" meddra_llt_id="10034350" meddra_pt="Peptic ulcer haemorrhage" meddra_pt_id="10034344" />
    </Mention>
    <Mention id="M64" len="24,9" reason="from_drug_use" section="S1" start="1777,1812" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Perforation small intestine" meddra_llt_id="10034429" meddra_pt="Small intestinal perforation" meddra_pt_id="10041103" />
    </Mention>
    <Mention id="M65" len="14,15" reason="from_drug_use" section="S1" start="1777,1806" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Perforation large intestine" meddra_llt_id="10034415" meddra_pt="Large intestine perforation" meddra_pt_id="10023804" />
    </Mention>
    <Mention id="M4" len="26" reason="preexisting_condition_or_risk_factor" section="S1" start="1853" type="Not_AE_Candidate">
      <Normalization meddra_llt="Inflammatory bowel disease" meddra_llt_id="10021972" meddra_pt="Inflammatory bowel disease" meddra_pt_id="10021972" />
    </Mention>
    <Mention id="M66" len="22" reason="from_drug_use" section="S1" start="1882" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Esophagitis ulcerative" meddra_llt_id="10062479" meddra_pt="Oesophagitis ulcerative" meddra_pt_id="10049098" />
    </Mention>
    <Mention id="M5" len="25" reason="manifestation_or_complication" section="S1" start="1923" type="NonOSE_AE">
      <Normalization meddra_llt="Nitrogen balance negative" meddra_llt_id="10029425" meddra_pt="Nitrogen balance negative" meddra_pt_id="10029425" />
    </Mention>
    <Mention id="M67" len="18" reason="from_drug_use" section="S1" start="1956" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Extreme catabolism" meddra_llt_id="10015872" meddra_pt="Hypercatabolism" meddra_pt_id="10049645" />
    </Mention>
    <Mention id="M68" len="27,5" reason="from_drug_use" section="S1" start="1999,2039" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Aseptic necrosis of head of humerus" meddra_llt_id="10003464" meddra_pt="Osteonecrosis" meddra_pt_id="10031264" />
    </Mention>
    <Mention id="M69" len="19,13" reason="from_drug_use" section="S1" start="1999,2031" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Aseptic necrosis of head of humerus" meddra_llt_id="10003464" meddra_pt="Osteonecrosis" meddra_pt_id="10031264" />
    </Mention>
    <Mention id="M70" len="19" reason="from_drug_use" section="S1" start="2046" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Atrophy muscle" meddra_llt_id="10003703" meddra_pt="Muscle atrophy" meddra_pt_id="10028289" />
    </Mention>
    <Mention id="M71" len="15" reason="from_drug_use" section="S1" start="2067" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscle weakness" meddra_llt_id="10028350" meddra_pt="Muscular weakness" meddra_pt_id="10028372" />
    </Mention>
    <Mention id="M72" len="12" reason="from_drug_use" section="S1" start="2084" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Osteoporosis" meddra_llt_id="10031282" meddra_pt="Osteoporosis" meddra_pt_id="10031282" />
    </Mention>
    <Mention id="M73" len="33" reason="from_drug_use" section="S1" start="2098" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pathologic fracture of neck of femur" meddra_llt_id="10034136" meddra_pt="Pathological fracture" meddra_pt_id="10034156" />
    </Mention>
    <Mention id="M74" len="16" reason="from_drug_use" section="S1" start="2133" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Steroid myopathy" meddra_llt_id="10042024" meddra_pt="Myopathy" meddra_pt_id="10028641" />
    </Mention>
    <Mention id="M75" len="14" reason="from_drug_use" section="S1" start="2151" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rupture tendon" meddra_llt_id="10039326" meddra_pt="Tendon rupture" meddra_pt_id="10043248" />
    </Mention>
    <Mention id="M76" len="31" reason="from_drug_use" section="S1" start="2167" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Spinal compression fracture" meddra_llt_id="10041541" meddra_pt="Spinal compression fracture" meddra_pt_id="10041541" />
    </Mention>
    <Mention id="M77" len="11" reason="from_drug_use" section="S1" start="2232" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Convulsions" meddra_llt_id="10010914" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M78" len="10" reason="from_drug_use" section="S1" start="2245" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety/depression" meddra_llt_id="10002872" meddra_pt="Depression" meddra_pt_id="10012378" />
    </Mention>
    <Mention id="M79" len="21" reason="from_drug_use" section="S1" start="2257" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Instability emotional" meddra_llt_id="10022454" meddra_pt="Affect lability" meddra_pt_id="10054196" />
    </Mention>
    <Mention id="M80" len="8" reason="from_drug_use" section="S1" start="2280" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Euphoria" meddra_llt_id="10015533" meddra_pt="Euphoric mood" meddra_pt_id="10015535" />
    </Mention>
    <Mention id="M81" len="8" reason="from_drug_use" section="S1" start="2290" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Headache" meddra_llt_id="10019211" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Mention>
    <Mention id="M82" len="31" reason="from_drug_use" section="S1" start="2300" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pressure intracranial increased" meddra_llt_id="10036647" meddra_pt="Intracranial pressure increased" meddra_pt_id="10022773" />
    </Mention>
    <Mention id="M107" len="11" reason="from_drug_use" section="S1" start="2337" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Papilledema" meddra_llt_id="10033703" meddra_pt="Papilloedema" meddra_pt_id="10033712" />
    </Mention>
    <Mention id="M108" len="19" reason="from_drug_use" section="S1" start="2350" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pseudotumor cerebri" meddra_llt_id="10037149" meddra_pt="Idiopathic intracranial hypertension" meddra_pt_id="10078904" />
    </Mention>
    <Mention id="M83" len="8" reason="from_drug_use" section="S1" start="2419" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M84" len="11" reason="from_drug_use" section="S1" start="2429" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mood swings" meddra_llt_id="10027951" meddra_pt="Mood swings" meddra_pt_id="10027951" />
    </Mention>
    <Mention id="M85" len="8" reason="from_drug_use" section="S1" start="2442" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neuritis" meddra_llt_id="10029240" meddra_pt="Neuritis" meddra_pt_id="10029240" />
    </Mention>
    <Mention id="M86" len="10" reason="from_drug_use" section="S1" start="2452" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neuropathy" meddra_llt_id="10029328" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M87" len="11" reason="from_drug_use" section="S1" start="2464" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Paresthesia" meddra_llt_id="10033987" meddra_pt="Paraesthesia" meddra_pt_id="10033775" />
    </Mention>
    <Mention id="M88" len="19" reason="from_drug_use" section="S1" start="2477" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Personality change" meddra_llt_id="10034719" meddra_pt="Personality change" meddra_pt_id="10034719" />
    </Mention>
    <Mention id="M89" len="17" reason="from_drug_use" section="S1" start="2498" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Psychic disorder" meddra_llt_id="10037181" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M90" len="7" reason="from_drug_use" section="S1" start="2517" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vertigo" meddra_llt_id="10047340" meddra_pt="Vertigo" meddra_pt_id="10047340" />
    </Mention>
    <Mention id="M91" len="12" reason="from_drug_use" section="S1" start="2544" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Exophthalmos" meddra_llt_id="10015683" meddra_pt="Exophthalmos" meddra_pt_id="10015683" />
    </Mention>
    <Mention id="M92" len="8" reason="from_drug_use" section="S1" start="2558" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Glaucoma" meddra_llt_id="10018304" meddra_pt="Glaucoma" meddra_pt_id="10018304" />
    </Mention>
    <Mention id="M93" len="30" reason="from_drug_use" section="S1" start="2568" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pressure intraocular increased" meddra_llt_id="10036648" meddra_pt="Intraocular pressure increased" meddra_pt_id="10022806" />
    </Mention>
    <Mention id="M94" len="31" reason="from_drug_use" section="S1" start="2600" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Posterior subcapsular cataract" meddra_llt_id="10036364" meddra_pt="Cataract subcapsular" meddra_pt_id="10007764" />
    </Mention>
    <Mention id="M95" len="21" reason="from_drug_use" section="S1" start="2646" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fat deposit facial" meddra_llt_id="10016244" meddra_pt="Fat tissue increased" meddra_pt_id="10016251" />
    </Mention>
    <Mention id="M96" len="33" reason="from_drug_use" section="S1" start="2669" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection susceptibility increased" meddra_llt_id="10021866" meddra_pt="Infection susceptibility increased" meddra_pt_id="10021866" />
    </Mention>
    <Mention id="M111" len="7" reason="from_drug_use" section="S1" start="2704" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hiccup" meddra_llt_id="10020038" meddra_pt="Hiccups" meddra_pt_id="10020039" />
    </Mention>
    <Mention id="M101" len="9,8,14" reason="from_drug_use" section="S1" start="2713,2736,2756" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Motility of spermatozoa increased or decreased" meddra_llt_id="10027989" meddra_pt="Spermatozoa progressive motility abnormal" meddra_pt_id="10041504" />
    </Mention>
    <Mention id="M103" len="9,21" reason="from_drug_use" section="S1" start="2713,2749" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sperm concentration increased" meddra_llt_id="10070926" meddra_pt="Sperm concentration increased" meddra_pt_id="10070926" />
    </Mention>
    <Mention id="M97" len="18,14" reason="from_drug_use" section="S1" start="2726,2756" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Spermatozoa progressive motility decreased" meddra_llt_id="10041506" meddra_pt="Spermatozoa progressive motility decreased" meddra_pt_id="10041506" />
    </Mention>
    <Mention id="M102" len="9,21" reason="from_drug_use" section="S1" start="2726,2749" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sperm concentration decreased" meddra_llt_id="10070925" meddra_pt="Sperm concentration decreased" meddra_pt_id="10070925" />
    </Mention>
    <Mention id="M98" len="7" reason="from_drug_use" section="S1" start="2772" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Malaise" meddra_llt_id="10025482" meddra_pt="Malaise" meddra_pt_id="10025482" />
    </Mention>
    <Mention id="M99" len="9" reason="from_drug_use" section="S1" start="2781" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Moon face" meddra_llt_id="10027953" meddra_pt="Cushingoid" meddra_pt_id="10011655" />
    </Mention>
    <Mention id="M100" len="11" reason="from_drug_use" section="S1" start="2792" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M195" len="16" reason="class_effect" section="S2" start="491" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Kaposi's sarcoma" meddra_llt_id="10023284" meddra_pt="Kaposi's sarcoma" meddra_pt_id="10023284" />
    </Mention>
    <Mention id="M196" len="16" reason="from_drug_use" section="S2" start="711" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sodium retention" meddra_llt_id="10041277" meddra_pt="Sodium retention" meddra_pt_id="10041277" />
    </Mention>
    <Mention id="M139" len="5" reason="manifestation_or_complication" section="S2" start="743" type="NonOSE_AE">
      <Normalization meddra_llt="Edema" meddra_llt_id="10014210" meddra_pt="Oedema" meddra_pt_id="10030095" />
    </Mention>
    <Mention id="M140" len="14" reason="manifestation_or_complication" section="S2" start="753" type="NonOSE_AE">
      <Normalization meddra_llt="Potassium low" meddra_llt_id="10036452" meddra_pt="Blood potassium decreased" meddra_pt_id="10005724" />
      <Normalization meddra_pt="Hypokalaemia" meddra_pt_id="10021015" />
    </Mention>
    <Mention id="M112" len="24" reason="preexisting_condition_or_risk_factor" section="S2" start="875" type="Not_AE_Candidate">
      <Normalization meddra_llt="Congestive heart failure" meddra_llt_id="10010684" meddra_pt="Cardiac failure congestive" meddra_pt_id="10007559" />
    </Mention>
    <Mention id="M113" len="12" reason="preexisting_condition_or_risk_factor" section="S2" start="901" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M114" len="19" reason="preexisting_condition_or_risk_factor" section="S2" start="918" type="Not_AE_Candidate">
      <Normalization meddra_llt="Renal insufficiency" meddra_llt_id="10038474" meddra_pt="Renal failure" meddra_pt_id="10038435" />
    </Mention>
    <Mention id="M198" len="51" reason="from_drug_use" section="S2" start="956" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Secondary adrenocortical insufficiency" meddra_llt_id="10039807" meddra_pt="Secondary adrenocortical insufficiency" meddra_pt_id="10039807" />
    </Mention>
    <Mention id="M115" len="6" reason="preexisting_condition_or_risk_factor" section="S2" start="1181" type="Not_AE_Candidate">
      <Normalization meddra_llt="Stress" meddra_llt_id="10042209" meddra_pt="Stress" meddra_pt_id="10042209" />
    </Mention>
    <Mention id="M183" len="27,8" reason="manifestation_or_complication" section="S2" start="1264,1299" type="NonOSE_AE">
      <Normalization meddra_llt="Mineralocorticoid deficiency" meddra_llt_id="10072080" meddra_pt="Mineralocorticoid deficiency" meddra_pt_id="10072080" />
    </Mention>
    <Mention id="M116" len="13" reason="preexisting_condition_or_risk_factor" section="S2" start="1460" type="Not_AE_Candidate">
      <Normalization meddra_llt="Peptic ulcer" meddra_llt_id="10034341" meddra_pt="Peptic ulcer" meddra_pt_id="10034341" />
    </Mention>
    <Mention id="M117" len="14" reason="preexisting_condition_or_risk_factor" section="S2" start="1475" type="Not_AE_Candidate">
      <Normalization meddra_llt="Diverticulitis" meddra_llt_id="10013538" meddra_pt="Diverticulitis" meddra_pt_id="10013538" />
    </Mention>
    <Mention id="M118" len="28" reason="preexisting_condition_or_risk_factor" section="S2" start="1491" type="Not_AE_Candidate">
      <Normalization meddra_llt="Intestinal anastomosis" meddra_llt_id="10057146" meddra_pt="Intestinal anastomosis" meddra_pt_id="10057146" />
    </Mention>
    <Mention id="M119" len="18" reason="preexisting_condition_or_risk_factor" section="S2" start="1537" type="Not_AE_Candidate">
      <Normalization meddra_llt="Colitis ulcerative" meddra_llt_id="10009900" meddra_pt="Colitis ulcerative" meddra_pt_id="10009900" />
    </Mention>
    <Mention id="M193" len="11" reason="AE_only_as_instruction" section="S2" start="1595" type="NonOSE_AE">
      <Normalization meddra_llt="Perforation" meddra_llt_id="10076705" meddra_pt="Perforation" meddra_pt_id="10076705" />
    </Mention>
    <Mention id="M141" len="21" reason="manifestation_or_complication" section="S2" start="1619" type="NonOSE_AE">
      <Normalization meddra_llt="Peritonitis perforative" meddra_llt_id="10034680" meddra_pt="Peritonitis" meddra_pt_id="10034674" />
    </Mention>
    <Mention id="M197" len="28" reason="class_effect" section="S2" start="1651" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gastrointestinal perforation" meddra_llt_id="10018001" meddra_pt="Gastrointestinal perforation" meddra_pt_id="10018001" />
    </Mention>
    <Mention id="M120" len="9" reason="preexisting_condition_or_risk_factor" section="S2" start="1838" type="Not_AE_Candidate">
      <Normalization meddra_llt="Micronodular cirrhosis" meddra_llt_id="10079256" meddra_pt="Hepatic cirrhosis" meddra_pt_id="10019641" />
    </Mention>
    <Mention id="M199" len="23" reason="class_effect" section="S2" start="1889" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bone formation decreased" meddra_llt_id="10056809" meddra_pt="Bone formation decreased" meddra_pt_id="10056809" />
    </Mention>
    <Mention id="M200" len="24" reason="class_effect" section="S2" start="1917" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Resorption bone increased" meddra_llt_id="10038642" meddra_pt="Resorption bone increased" meddra_pt_id="10038642" />
    </Mention>
    <Mention id="M229" len="28" reason="class_effect" section="S2" start="1961" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Calcium metabolism disorder" meddra_llt_id="10006974" meddra_pt="Calcium metabolism disorder" meddra_pt_id="10006974" />
    </Mention>
    <Mention id="M201" len="7,21" reason="class_effect" section="S2" start="1971,1997" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Calcium deficiency" meddra_llt_id="10006956" meddra_pt="Calcium deficiency" meddra_pt_id="10006956" />
    </Mention>
    <Mention id="M202" len="7,20" reason="class_effect" section="S2" start="1971,2023" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Urine calcium increased" meddra_llt_id="10050278" meddra_pt="Urine calcium increased" meddra_pt_id="10050278" />
    </Mention>
    <Mention id="M203" len="33" reason="class_effect" section="S2" start="2049" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bone metabolism disorder" meddra_llt_id="10058972" meddra_pt="Bone metabolism disorder" meddra_pt_id="10058972" />
    </Mention>
    <Mention id="M187" len="42" reason="manifestation_or_complication" section="S2" start="2106" type="NonOSE_AE">
      <Normalization meddra_llt="Bone metabolism disorder" meddra_llt_id="10058972" meddra_pt="Bone metabolism disorder" meddra_pt_id="10058972" />
    </Mention>
    <Mention id="M204" len="30" reason="class_effect" section="S2" start="2165" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Extreme catabolism" meddra_llt_id="10015872" meddra_pt="Hypercatabolism" meddra_pt_id="10049645" />
    </Mention>
    <Mention id="M205" len="30" reason="class_effect" section="S2" start="2201" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sex hormone binding globulin decreased" meddra_llt_id="10059660" meddra_pt="Sex hormone binding globulin decreased" meddra_pt_id="10059660" />
    </Mention>
    <Mention id="M206" len="25" reason="class_effect" section="S2" start="2245" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Arrest of bone development or growth" meddra_llt_id="10003112" meddra_pt="Bone development abnormal" meddra_pt_id="10005954" />
    </Mention>
    <Mention id="M207" len="12" reason="class_effect" section="S2" start="2316" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Osteoporosis" meddra_llt_id="10031282" meddra_pt="Osteoporosis" meddra_pt_id="10031282" />
    </Mention>
    <Mention id="M138" len="12" reason="preexisting_condition_or_risk_factor" section="S2" start="2412" type="Not_AE_Candidate">
      <Normalization meddra_llt="Osteoporosis" meddra_llt_id="10031282" meddra_pt="Osteoporosis" meddra_pt_id="10031282" />
    </Mention>
    <Mention id="M121" len="14" reason="preexisting_condition_or_risk_factor" section="S2" start="2432" type="Not_AE_Candidate">
      <Normalization meddra_llt="Postmenopause" meddra_llt_id="10051775" meddra_pt="Postmenopause" meddra_pt_id="10051775" />
    </Mention>
    <Mention id="M122" len="41" reason="preexisting_condition_or_risk_factor" section="S2" start="2631" type="Not_AE_Candidate">
      <Normalization meddra_llt="Multiple sclerosis exacerbation" meddra_llt_id="10070425" meddra_pt="Multiple sclerosis relapse" meddra_pt_id="10048393" />
    </Mention>
    <Mention id="M208" len="14" reason="class_effect" section="S2" start="2924" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Acute myopathy" meddra_llt_id="10066646" meddra_pt="Myopathy" meddra_pt_id="10028641" />
    </Mention>
    <Mention id="M123" len="39" reason="preexisting_condition_or_risk_factor" section="S2" start="3042" type="Not_AE_Candidate">
      <Normalization meddra_llt="Neuromuscular disorder NOS" meddra_llt_id="10029316" meddra_pt="Neuromyopathy" meddra_pt_id="10029323" />
      <Normalization meddra_pt="Neuromuscular toxicity" meddra_pt_id="10062284" />
    </Mention>
    <Mention id="M124" len="17" reason="preexisting_condition_or_risk_factor" section="S2" start="3089" type="Not_AE_Candidate">
      <Normalization meddra_llt="Myasthenia gravis" meddra_llt_id="10028417" meddra_pt="Myasthenia gravis" meddra_pt_id="10028417" />
    </Mention>
    <Mention id="M142" len="14" reason="AE_only_as_instruction" section="S2" start="3214" type="NonOSE_AE">
      <Normalization meddra_llt="Acute myopathy" meddra_llt_id="10066646" meddra_pt="Myopathy" meddra_pt_id="10028641" />
    </Mention>
    <Mention id="M143" len="13" reason="manifestation_or_complication" section="S2" start="3307" type="NonOSE_AE">
      <Normalization meddra_llt="Quadriparesis" meddra_llt_id="10049680" meddra_pt="Quadriparesis" meddra_pt_id="10049680" />
    </Mention>
    <Mention id="M209" len="30" reason="class_effect" section="S2" start="3322" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Creatinine blood increased" meddra_llt_id="10011361" meddra_pt="Blood creatinine increased" meddra_pt_id="10005483" />
    </Mention>
    <Mention id="M210" len="20" reason="class_effect" section="S2" start="3458" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Psychic disorder" meddra_llt_id="10037181" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M211" len="8" reason="class_effect" section="S2" start="3534" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Euphoria" meddra_llt_id="10015533" meddra_pt="Euphoric mood" meddra_pt_id="10015535" />
    </Mention>
    <Mention id="M212" len="8" reason="class_effect" section="S2" start="3544" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M213" len="11" reason="class_effect" section="S2" start="3554" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mood swings" meddra_llt_id="10027951" meddra_pt="Mood swings" meddra_pt_id="10027951" />
    </Mention>
    <Mention id="M214" len="19" reason="class_effect" section="S2" start="3567" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Personality change" meddra_llt_id="10034719" meddra_pt="Personality change" meddra_pt_id="10034719" />
    </Mention>
    <Mention id="M215" len="17" reason="class_effect" section="S2" start="3592" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Depression" meddra_llt_id="10012378" meddra_pt="Depression" meddra_pt_id="10012378" />
    </Mention>
    <Mention id="M216" len="24" reason="class_effect" section="S2" start="3620" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Psychotic symptom" meddra_llt_id="10079254" meddra_pt="Psychotic symptom" meddra_pt_id="10079254" />
    </Mention>
    <Mention id="M217" len="21,10" reason="class_effect" section="S2" start="3661,3714" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Instability emotional" meddra_llt_id="10022454" meddra_pt="Affect lability" meddra_pt_id="10054196" />
    </Mention>
    <Mention id="M218" len="20,10" reason="class_effect" section="S2" start="3686,3714" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Psychotic behaviour" meddra_llt_id="10037249" meddra_pt="Psychotic behaviour" meddra_pt_id="10037249" />
    </Mention>
    <Mention id="M219" len="20,8" reason="class_effect" section="S2" start="3764,3796" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pressure intraocular increased" meddra_llt_id="10036648" meddra_pt="Intraocular pressure increased" meddra_pt_id="10022806" />
    </Mention>
    <Mention id="M192" len="21" reason="AE_only_as_instruction" section="S2" start="4096" type="NonOSE_AE">
      <Normalization meddra_llt="Insufficiency adrenal" meddra_llt_id="10022460" meddra_pt="Adrenal insufficiency" meddra_pt_id="10001367" />
    </Mention>
    <Mention id="M194" len="9" reason="AE_only_as_instruction" section="S2" start="4136" type="NonOSE_AE">
      <Normalization meddra_llt="Drug dependence" meddra_llt_id="10013663" meddra_pt="Drug dependence" meddra_pt_id="10013663" />
    </Mention>
    <Mention id="M144" len="13" reason="AE_only_as_instruction" section="S2" start="4312" type="NonOSE_AE">
      <Normalization meddra_llt="Illness" meddra_llt_id="10080284" meddra_pt="Ill-defined disorder" meddra_pt_id="10061520" />
    </Mention>
    <Mention id="M145" len="5" reason="AE_only_as_instruction" section="S2" start="4336" type="NonOSE_AE">
      <Normalization meddra_llt="Fever" meddra_llt_id="10016558" meddra_pt="Pyrexia" meddra_pt_id="10037660" />
    </Mention>
    <Mention id="M146" len="9" reason="AE_only_as_instruction" section="S2" start="4360" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M147" len="34" reason="OD_or_withdrawal" section="S2" start="4460" type="NonOSE_AE">
      <Normalization meddra_llt="Corticosteroid withdrawal syndrome" meddra_llt_id="10011173" meddra_pt="Steroid withdrawal syndrome" meddra_pt_id="10042028" />
    </Mention>
    <Mention id="M148" len="7" reason="OD_or_withdrawal" section="S2" start="4506" type="NonOSE_AE">
      <Normalization meddra_llt="Myalgia" meddra_llt_id="10028411" meddra_pt="Myalgia" meddra_pt_id="10028411" />
    </Mention>
    <Mention id="M149" len="10" reason="OD_or_withdrawal" section="S2" start="4515" type="NonOSE_AE">
      <Normalization meddra_llt="Arthralgia" meddra_llt_id="10003239" meddra_pt="Arthralgia" meddra_pt_id="10003239" />
    </Mention>
    <Mention id="M150" len="7" reason="OD_or_withdrawal" section="S2" start="4531" type="NonOSE_AE">
      <Normalization meddra_llt="Malaise" meddra_llt_id="10025482" meddra_pt="Malaise" meddra_pt_id="10025482" />
    </Mention>
    <Mention id="M151" len="10" reason="AE_only_as_instruction" section="S2" start="4615" type="NonOSE_AE">
      <Normalization meddra_llt="Chickenpox" meddra_llt_id="10008505" meddra_pt="Varicella" meddra_pt_id="10046980" />
    </Mention>
    <Mention id="M152" len="7" reason="AE_only_as_instruction" section="S2" start="4629" type="NonOSE_AE">
      <Normalization meddra_llt="Measles" meddra_llt_id="10027011" meddra_pt="Measles" meddra_pt_id="10027011" />
    </Mention>
    <Mention id="M153" len="28" reason="AE_from_drug_interaction" section="S2" start="4813" type="NonOSE_AE">
      <Normalization meddra_llt="Drug-drug pharmacodynamic interaction" meddra_llt_id="10065993" meddra_pt="Drug interaction" meddra_pt_id="10013710" />
    </Mention>
    <Mention id="M154" len="11" reason="AE_from_drug_interaction" section="S2" start="5098" type="NonOSE_AE">
      <Normalization meddra_llt="Hypokalemia" meddra_llt_id="10021018" meddra_pt="Hypokalaemia" meddra_pt_id="10021015" />
      <Normalization meddra_pt="Blood potassium decreased" meddra_pt_id="10005724" />
    </Mention>
    <Mention id="M156" len="19" reason="AE_from_drug_interaction" section="S2" start="5233" type="NonOSE_AE">
      <Normalization meddra_llt="Enlargement heart" meddra_llt_id="10014846" meddra_pt="Cardiomegaly" meddra_pt_id="10007632" />
    </Mention>
    <Mention id="M155" len="24" reason="AE_from_drug_interaction" section="S2" start="5257" type="NonOSE_AE">
      <Normalization meddra_llt="Congestive heart failure" meddra_llt_id="10010684" meddra_pt="Cardiac failure congestive" meddra_pt_id="10007559" />
    </Mention>
    <Mention id="M157" len="15" reason="AE_from_drug_interaction" section="S2" start="5582" type="NonOSE_AE">
      <Normalization meddra_llt="Weakness" meddra_llt_id="10047862" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M125" len="17" reason="preexisting_condition_or_risk_factor" section="S2" start="5615" type="Not_AE_Candidate">
      <Normalization meddra_llt="Myasthenia gravis" meddra_llt_id="10028417" meddra_pt="Myasthenia gravis" meddra_pt_id="10028417" />
    </Mention>
    <Mention id="M158" len="20" reason="AE_only_as_instruction" section="S2" start="6022" type="NonOSE_AE">
      <Normalization meddra_llt="Decreased anticoagulant effect" meddra_llt_id="10011956" meddra_pt="Coagulation time shortened" meddra_pt_id="10009800" />
    </Mention>
    <Mention id="M220" len="37" reason="class_effect" section="S2" start="6092" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Blood glucose increased" meddra_llt_id="10005557" meddra_pt="Blood glucose increased" meddra_pt_id="10005557" />
      <Normalization meddra_pt="Impaired fasting glucose" meddra_pt_id="10056997" />
    </Mention>
    <Mention id="M159" len="11" reason="AE_from_drug_interaction" section="S2" start="6477" type="NonOSE_AE">
      <Normalization meddra_llt="Convulsions" meddra_llt_id="10010914" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M160" len="65" reason="AE_from_drug_interaction" section="S2" start="6577" type="NonOSE_AE">
      <Normalization meddra_llt="False negative investigation result" meddra_llt_id="10070747" meddra_pt="False negative investigation result" meddra_pt_id="10070747" />
    </Mention>
    <Mention id="M161" len="11" reason="AE_from_drug_interaction" section="S2" start="6875" type="NonOSE_AE">
      <Normalization meddra_llt="Arrhythmia" meddra_llt_id="10003119" meddra_pt="Arrhythmia" meddra_pt_id="10003119" />
    </Mention>
    <Mention id="M162" len="11" reason="AE_from_drug_interaction" section="S2" start="6894" type="NonOSE_AE">
      <Normalization meddra_llt="Hypokalemia" meddra_llt_id="10021018" meddra_pt="Hypokalaemia" meddra_pt_id="10021015" />
      <Normalization meddra_pt="Blood potassium decreased" meddra_pt_id="10005724" />
    </Mention>
    <Mention id="M163" len="40" reason="AE_only_as_instruction" section="S2" start="8175" type="NonOSE_AE">
      <Normalization meddra_llt="Insufficiency adrenal" meddra_llt_id="10022460" meddra_pt="Adrenal insufficiency" meddra_pt_id="10001367" />
    </Mention>
    <Mention id="M164" len="21" reason="AE_from_drug_interaction" section="S2" start="8230" type="NonOSE_AE">
      <Normalization meddra_llt="Insufficiency adrenal" meddra_llt_id="10022460" meddra_pt="Adrenal insufficiency" meddra_pt_id="10001367" />
    </Mention>
    <Mention id="M165" len="29" reason="AE_from_drug_interaction" section="S2" start="8456" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M126" len="19" reason="preexisting_condition_or_risk_factor" section="S2" start="8560" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hypoprothrombinemia" meddra_llt_id="10054431" meddra_pt="Hypoprothrombinaemia" meddra_pt_id="10021085" />
    </Mention>
    <Mention id="M166" len="7" reason="AE_from_drug_interaction" section="S2" start="8853" type="NonOSE_AE">
      <Normalization meddra_llt="Seizure" meddra_llt_id="10039906" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M167" len="32" reason="AE_from_drug_interaction" section="S2" start="8907" type="NonOSE_AE">
      <Normalization meddra_llt="False negative investigation result" meddra_llt_id="10070747" meddra_pt="False negative investigation result" meddra_pt_id="10070747" />
    </Mention>
    <Mention id="M168" len="26" reason="AE_from_drug_interaction" section="S2" start="9028" type="NonOSE_AE">
      <Normalization meddra_llt="Toxic epidermal necrolysis" meddra_llt_id="10044223" meddra_pt="Toxic epidermal necrolysis" meddra_pt_id="10044223" />
    </Mention>
    <Mention id="M169" len="31" reason="AE_from_drug_interaction" section="S2" start="9230" type="NonOSE_AE">
      <Normalization meddra_llt="Immunosuppression" meddra_llt_id="10062016" meddra_pt="Immunosuppression" meddra_pt_id="10062016" />
    </Mention>
    <Mention id="M190" len="82" reason="AE_from_drug_interaction" section="S2" start="9288" type="NonOSE_AE">
      <Normalization meddra_llt="Vaccination complication" meddra_llt_id="10046861" meddra_pt="Vaccination complication" meddra_pt_id="10046861" />
    </Mention>
    <Mention id="M170" len="14" reason="AE_only_as_instruction" section="S2" start="9717" type="NonOSE_AE">
      <Normalization meddra_llt="Carcinogenicity" meddra_llt_id="10007269" meddra_pt="Carcinogenicity" meddra_pt_id="10007269" />
    </Mention>
    <Mention id="M171" len="11" reason="AE_only_as_instruction" section="S2" start="9735" type="NonOSE_AE">
      <Normalization meddra_llt="Mutagenic effect" meddra_llt_id="10028400" meddra_pt="Mutagenic effect" meddra_pt_id="10028400" />
    </Mention>
    <Mention id="M221" len="8,8,14" reason="class_effect" section="S2" start="9763,9784,9804" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Motility of spermatozoa increased or decreased" meddra_llt_id="10027989" meddra_pt="Spermatozoa progressive motility abnormal" meddra_pt_id="10041504" />
    </Mention>
    <Mention id="M222" len="8,21" reason="class_effect" section="S2" start="9763,9797" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sperm concentration increased" meddra_llt_id="10070926" meddra_pt="Sperm concentration increased" meddra_pt_id="10070926" />
    </Mention>
    <Mention id="M223" len="8,21" reason="class_effect" section="S2" start="9775,9797" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Spermatozoa progressive motility decreased" meddra_llt_id="10041506" meddra_pt="Spermatozoa progressive motility decreased" meddra_pt_id="10041506" />
    </Mention>
    <Mention id="M224" len="8,21" reason="class_effect" section="S2" start="9775,9797" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sperm concentration decreased" meddra_llt_id="10070925" meddra_pt="Sperm concentration decreased" meddra_pt_id="10070925" />
    </Mention>
    <Mention id="M172" len="9" reason="AE_only_as_instruction" section="S2" start="9877" type="NonOSE_AE">
      <Normalization meddra_llt="Pregnancy" meddra_llt_id="10036556" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M191" len="11" reason="AE_animal" section="S2" start="9941" type="NonOSE_AE">
      <Normalization meddra_llt="Teratogenicity" meddra_llt_id="10043275" meddra_pt="Teratogenicity" meddra_pt_id="10043275" />
      <Normalization meddra_pt="Foetal damage" meddra_pt_id="10016852" />
      <Normalization meddra_pt="Maternal drugs affecting foetus" meddra_pt_id="10026923" />
    </Mention>
    <Mention id="M173" len="8" reason="AE_animal" section="S2" start="10078" type="NonOSE_AE">
      <Normalization meddra_llt="Pregnant" meddra_llt_id="10036586" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M174" len="29" reason="AE_animal" section="S2" start="10150" type="NonOSE_AE">
      <Normalization meddra_llt="Palate cleft" meddra_llt_id="10033529" meddra_pt="Cleft palate" meddra_pt_id="10009269" />
    </Mention>
    <Mention id="M127" len="8" reason="preexisting_condition_or_risk_factor" section="S2" start="10234" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pregnant" meddra_llt_id="10036586" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M128" len="9" reason="preexisting_condition_or_risk_factor" section="S2" start="10288" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pregnancy" meddra_llt_id="10036556" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M230" len="17" reason="from_drug_use" section="S2" start="10352" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Maternal drugs affecting fetus" meddra_llt_id="10060521" meddra_pt="Maternal drugs affecting foetus" meddra_pt_id="10026923" />
      <Normalization meddra_pt="Teratogenicity" meddra_pt_id="10043275" />
      <Normalization meddra_pt="Foetal damage" meddra_pt_id="10016852" />
    </Mention>
    <Mention id="M175" len="7,14" reason="AE_only_as_instruction" section="S2" start="10371,10509" type="NonOSE_AE">
      <Normalization meddra_llt="Adrenal insufficiency neonatal" meddra_llt_id="10001368" meddra_pt="Adrenal insufficiency neonatal" meddra_pt_id="10001368" />
    </Mention>
    <Mention id="M129" len="9" reason="preexisting_condition_or_risk_factor" section="S2" start="10457" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pregnancy" meddra_llt_id="10036556" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M225" len="15" reason="class_effect" section="S2" start="10622" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Growth retardation" meddra_llt_id="10053759" meddra_pt="Growth retardation" meddra_pt_id="10053759" />
    </Mention>
    <Mention id="M226" len="51" reason="class_effect" section="S2" start="10639" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Blood corticosterone abnormal" meddra_llt_id="10005446" meddra_pt="Blood corticosterone abnormal" meddra_pt_id="10005446" />
    </Mention>
    <Mention id="M231" len="57" reason="from_drug_use" section="S2" start="10762" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Transmission of drug via breast milk" meddra_llt_id="10050426" meddra_pt="Exposure during breast feeding" meddra_pt_id="10071402" />
    </Mention>
    <Mention id="M130" len="18" reason="indication" section="S2" start="11286" type="Not_AE_Candidate">
      <Normalization meddra_llt="Nephrotic syndrome" meddra_llt_id="10029164" meddra_pt="Nephrotic syndrome" meddra_pt_id="10029164" />
    </Mention>
    <Mention id="M131" len="9" reason="indication" section="S2" start="11348" type="Not_AE_Candidate">
      <Normalization meddra_llt="Lymphoma" meddra_llt_id="10025310" meddra_pt="Lymphoma" meddra_pt_id="10025310" />
    </Mention>
    <Mention id="M132" len="9" reason="indication" section="S2" start="11362" type="Not_AE_Candidate">
      <Normalization meddra_llt="Leukemia" meddra_llt_id="10024329" meddra_pt="Leukaemia" meddra_pt_id="10024288" />
    </Mention>
    <Mention id="M133" len="6" reason="indication" section="S2" start="11469" type="Not_AE_Candidate">
      <Normalization meddra_llt="Asthma" meddra_llt_id="10003553" meddra_pt="Asthma" meddra_pt_id="10003553" />
    </Mention>
    <Mention id="M134" len="8" reason="indication" section="S2" start="11480" type="Not_AE_Candidate">
      <Normalization meddra_llt="Wheezing" meddra_llt_id="10047924" meddra_pt="Wheezing" meddra_pt_id="10047924" />
    </Mention>
    <Mention id="M176" len="9" reason="AE_only_as_instruction" section="S2" start="12012" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M177" len="25" reason="AE_only_as_instruction" section="S2" start="12023" type="NonOSE_AE">
      <Normalization meddra_llt="Psychiatric symptom" meddra_llt_id="10061472" meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
      <Normalization meddra_pt="Mental disorder" meddra_pt_id="10061284" />
    </Mention>
    <Mention id="M178" len="15" reason="AE_only_as_instruction" section="S2" start="12050" type="NonOSE_AE">
      <Normalization meddra_llt="Thromboembolism" meddra_llt_id="10043566" meddra_pt="Embolism" meddra_pt_id="10061169" />
    </Mention>
    <Mention id="M179" len="13" reason="AE_only_as_instruction" section="S2" start="12067" type="NonOSE_AE">
      <Normalization meddra_llt="Peptic ulcer" meddra_llt_id="10034341" meddra_pt="Peptic ulcer" meddra_pt_id="10034341" />
    </Mention>
    <Mention id="M180" len="9" reason="AE_only_as_instruction" section="S2" start="12082" type="NonOSE_AE">
      <Normalization meddra_llt="Cataracts" meddra_llt_id="10007771" meddra_pt="Cataract" meddra_pt_id="10007739" />
    </Mention>
    <Mention id="M181" len="12" reason="AE_only_as_instruction" section="S2" start="12097" type="NonOSE_AE">
      <Normalization meddra_llt="Osteoporosis" meddra_llt_id="10031282" meddra_pt="Osteoporosis" meddra_pt_id="10031282" />
    </Mention>
    <Mention id="M227" len="33" reason="class_effect" section="S2" start="12251" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Growth retardation" meddra_llt_id="10053759" meddra_pt="Growth retardation" meddra_pt_id="10053759" />
    </Mention>
    <Mention id="M228" len="15,9" reason="class_effect" section="S2" start="12291,12326" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Growth retardation" meddra_llt_id="10053759" meddra_pt="Growth retardation" meddra_pt_id="10053759" />
    </Mention>
    <Mention id="M182" len="53" reason="negation" section="S2" start="12421" type="NonOSE_AE">
      <Normalization meddra_llt="Hypothalamic pituitary adrenal axis suppression" meddra_llt_id="10074052" meddra_pt="Hypothalamic pituitary adrenal axis suppression" meddra_pt_id="10074052" />
    </Mention>
    <Mention id="M188" len="14" reason="AE_only_as_instruction" section="S2" start="12819" type="NonOSE_AE">
      <Normalization meddra_llt="Growth retardation" meddra_llt_id="10053759" meddra_pt="Growth retardation" meddra_pt_id="10053759" />
    </Mention>
    <Mention id="M189" len="14" reason="AE_only_as_instruction" section="S2" start="12993" type="NonOSE_AE">
      <Normalization meddra_llt="Growth retardation" meddra_llt_id="10053759" meddra_pt="Growth retardation" meddra_pt_id="10053759" />
    </Mention>
    <Mention id="M135" len="17,8" reason="preexisting_condition_or_risk_factor" section="S2" start="13549,13586" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hepatic function decreased" meddra_llt_id="10019673" meddra_pt="Hepatic function abnormal" meddra_pt_id="10019670" />
    </Mention>
    <Mention id="M136" len="9,5,8" reason="preexisting_condition_or_risk_factor" section="S2" start="13549,13568,13586" type="Not_AE_Candidate">
      <Normalization meddra_llt="Impaired renal function" meddra_llt_id="10021523" meddra_pt="Renal impairment" meddra_pt_id="10062237" />
    </Mention>
    <Mention id="M137" len="9,16" reason="preexisting_condition_or_risk_factor" section="S2" start="13549,13578" type="Not_AE_Candidate">
      <Normalization meddra_llt="Cardiac dysfunction" meddra_llt_id="10079751" meddra_pt="Cardiac dysfunction" meddra_pt_id="10079751" />
    </Mention>
    <Mention id="M186" len="17" reason="AE_only_as_instruction" section="S2" start="13683" type="NonOSE_AE">
      <Normalization meddra_llt="Diabetes mellitus" meddra_llt_id="10012601" meddra_pt="Diabetes mellitus" meddra_pt_id="10012601" />
    </Mention>
    <Mention id="M184" len="15" reason="AE_only_as_instruction" section="S2" start="13702" type="NonOSE_AE">
      <Normalization meddra_llt="Fluid retention" meddra_llt_id="10016807" meddra_pt="Fluid retention" meddra_pt_id="10016807" />
    </Mention>
    <Mention id="M185" len="12" reason="AE_only_as_instruction" section="S2" start="13722" type="NonOSE_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M278" len="23" reason="class_effect" section="S3" start="45" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anaphylactoid reaction" meddra_llt_id="10002216" meddra_pt="Anaphylactoid reaction" meddra_pt_id="10002216" />
    </Mention>
    <Mention id="M232" len="6" reason="preexisting_condition_or_risk_factor" section="S3" start="288" type="Not_AE_Candidate">
      <Normalization meddra_llt="Stress" meddra_llt_id="10042209" meddra_pt="Stress" meddra_pt_id="10042209" />
    </Mention>
    <Mention id="M233" len="9" reason="preexisting_condition_or_risk_factor" section="S3" start="325" type="Not_AE_Candidate">
      <Normalization meddra_llt="Stress" meddra_llt_id="10042209" meddra_pt="Stress" meddra_pt_id="10042209" />
    </Mention>
    <Mention id="M279" len="27" reason="class_effect" section="S3" start="420" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Increased blood pressure" meddra_llt_id="10021655" meddra_pt="Blood pressure increased" meddra_pt_id="10005750" />
    </Mention>
    <Mention id="M280" len="6,9" reason="class_effect" section="S3" start="449,466" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sodium retention" meddra_llt_id="10041277" meddra_pt="Sodium retention" meddra_pt_id="10041277" />
    </Mention>
    <Mention id="M281" len="15" reason="class_effect" section="S3" start="460" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Retention water" meddra_llt_id="10038785" meddra_pt="Fluid retention" meddra_pt_id="10016807" />
    </Mention>
    <Mention id="M282" len="32" reason="class_effect" section="S3" start="481" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Urine potassium increased" meddra_llt_id="10046663" meddra_pt="Urine potassium increased" meddra_pt_id="10046663" />
    </Mention>
    <Mention id="M283" len="26" reason="class_effect" section="S3" start="711" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Urine calcium increased" meddra_llt_id="10050278" meddra_pt="Urine calcium increased" meddra_pt_id="10050278" />
    </Mention>
    <Mention id="M284" len="34" reason="class_effect" section="S3" start="827" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ventricle rupture" meddra_llt_id="10047279" meddra_pt="Ventricle rupture" meddra_pt_id="10047279" />
    </Mention>
    <Mention id="M234" len="21" reason="preexisting_condition_or_risk_factor" section="S3" start="877" type="Not_AE_Candidate">
      <Normalization meddra_llt="Myocardial infarction" meddra_llt_id="10028596" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M285" len="53" reason="class_effect" section="S3" start="1050" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypothalamic pituitary adrenal axis suppression" meddra_llt_id="10074052" meddra_pt="Hypothalamic pituitary adrenal axis suppression" meddra_pt_id="10074052" />
    </Mention>
    <Mention id="M251" len="28" reason="OD_or_withdrawal" section="S3" start="1127" type="NonOSE_AE">
      <Normalization meddra_llt="Insufficiency adrenal" meddra_llt_id="10022460" meddra_pt="Adrenal insufficiency" meddra_pt_id="10001367" />
    </Mention>
    <Mention id="M252" len="28" reason="OD_or_withdrawal" section="S3" start="1187" type="NonOSE_AE">
      <Normalization meddra_llt="Corticoadrenal insufficiency" meddra_llt_id="10011172" meddra_pt="Adrenal insufficiency" meddra_pt_id="10001367" />
    </Mention>
    <Mention id="M235" len="6" reason="preexisting_condition_or_risk_factor" section="S3" start="1449" type="Not_AE_Candidate">
      <Normalization meddra_llt="Stress" meddra_llt_id="10042209" meddra_pt="Stress" meddra_pt_id="10042209" />
    </Mention>
    <Mention id="M236" len="11" reason="preexisting_condition_or_risk_factor" section="S3" start="1662" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hypothyroidism" meddra_llt_id="10021114" meddra_pt="Hypothyroidism" meddra_pt_id="10021114" />
    </Mention>
    <Mention id="M237" len="12" reason="preexisting_condition_or_risk_factor" section="S3" start="1700" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hyperthyroidism" meddra_llt_id="10020850" meddra_pt="Hyperthyroidism" meddra_pt_id="10020850" />
    </Mention>
    <Mention id="M253" len="25" reason="AE_only_as_instruction" section="S3" start="1723" type="NonOSE_AE">
      <Normalization meddra_llt="Thyroid disorder" meddra_llt_id="10043709" meddra_pt="Thyroid disorder" meddra_pt_id="10043709" />
    </Mention>
    <Mention id="M308" len="25" reason="class_effect" section="S3" start="1879" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Increased susceptibility to infections NOS" meddra_llt_id="10021686" meddra_pt="Infection susceptibility increased" meddra_pt_id="10021866" />
    </Mention>
    <Mention id="M254" len="9" reason="AE_only_as_instruction" section="S3" start="1995" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M286" len="9" reason="class_effect" section="S3" start="2036" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M287" len="9,5" reason="class_effect" section="S3" start="2036,2065" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection viral" meddra_llt_id="10021876" meddra_pt="Viral infection" meddra_pt_id="10047461" />
      <Normalization meddra_pt="Infection reactivation" meddra_pt_id="10070891" />
    </Mention>
    <Mention id="M288" len="9,9" reason="class_effect" section="S3" start="2036,2072" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bacterial infection" meddra_llt_id="10060945" meddra_pt="Bacterial infection" meddra_pt_id="10060945" />
    </Mention>
    <Mention id="M289" len="9,6" reason="class_effect" section="S3" start="2036,2083" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection fungal" meddra_llt_id="10021814" meddra_pt="Fungal infection" meddra_pt_id="10017533" />
    </Mention>
    <Mention id="M290" len="9,9" reason="class_effect" section="S3" start="2036,2091" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection protozoal" meddra_llt_id="10021859" meddra_pt="Infection protozoal" meddra_pt_id="10021859" />
    </Mention>
    <Mention id="M291" len="9,10" reason="class_effect" section="S3" start="2036,2104" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Helminthic infection" meddra_llt_id="10061201" meddra_pt="Helminthic infection" meddra_pt_id="10061201" />
    </Mention>
    <Mention id="M275" len="24" reason="AE_only_as_instruction" section="S3" start="2229" type="NonOSE_AE">
      <Normalization meddra_llt="Immunosuppressant drug therapy" meddra_llt_id="10054980" meddra_pt="Immunosuppressant drug therapy" meddra_pt_id="10054980" />
    </Mention>
    <Mention id="M255" len="10" reason="AE_only_as_instruction" section="S3" start="2261" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M256" len="34" reason="AE_only_as_instruction" section="S3" start="2363" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M309" len="4,9" reason="class_effect" section="S3" start="2424,2451" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection masked" meddra_llt_id="10021836" meddra_pt="Infection masked" meddra_pt_id="10021836" />
    </Mention>
    <Mention id="M276" len="17" reason="general_term" section="S3" start="2465" type="NonOSE_AE">
      <Normalization meddra_llt="Infection fungal" meddra_llt_id="10021814" meddra_pt="Fungal infection" meddra_pt_id="10017533" />
    </Mention>
    <Mention id="M310" len="37" reason="class_effect" section="S3" start="2505" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Systemic fungal infection NOS" meddra_llt_id="10042941" meddra_pt="Systemic mycosis" meddra_pt_id="10052366" />
    </Mention>
    <Mention id="M257" len="10" reason="AE_only_as_instruction" section="S3" start="2600" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M258" len="31" reason="AE_only_as_instruction" section="S3" start="2645" type="NonOSE_AE">
      <Normalization meddra_llt="Adverse drug reaction" meddra_llt_id="10061623" meddra_pt="Adverse drug reaction" meddra_pt_id="10061623" />
    </Mention>
    <Mention id="M260" len="19" reason="AE_from_drug_interaction" section="S3" start="2787" type="NonOSE_AE">
      <Normalization meddra_llt="Enlargement heart" meddra_llt_id="10014846" meddra_pt="Cardiomegaly" meddra_pt_id="10007632" />
    </Mention>
    <Mention id="M259" len="24" reason="AE_from_drug_interaction" section="S3" start="2811" type="NonOSE_AE">
      <Normalization meddra_llt="Congestive heart failure" meddra_llt_id="10010684" meddra_pt="Cardiac failure congestive" meddra_pt_id="10007559" />
    </Mention>
    <Mention id="M292" len="10,6" reason="class_effect" section="S3" start="3047,3102" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Amoeba histolytica infection NOS" meddra_llt_id="10001979" meddra_pt="Amoebiasis" meddra_pt_id="10001980" />
    </Mention>
    <Mention id="M297" len="10,7" reason="class_effect" section="S3" start="3047,3112" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Candida infection" meddra_llt_id="10074170" meddra_pt="Candida infection" meddra_pt_id="10074170" />
    </Mention>
    <Mention id="M298" len="10" reason="class_effect" section="S3" start="3047" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M299" len="10,12" reason="class_effect" section="S3" start="3047,3123" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cryptococcus neoformans infection" meddra_llt_id="10011493" meddra_pt="Cryptococcosis" meddra_pt_id="10011490" />
    </Mention>
    <Mention id="M300" len="10,13" reason="class_effect" section="S3" start="3047,3139" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mycobacterial infection" meddra_llt_id="10062207" meddra_pt="Mycobacterial infection" meddra_pt_id="10062207" />
    </Mention>
    <Mention id="M301" len="10,8" reason="class_effect" section="S3" start="3047,3156" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nocardia infection" meddra_llt_id="10064083" meddra_pt="Nocardiosis" meddra_pt_id="10029444" />
    </Mention>
    <Mention id="M302" len="10,12" reason="class_effect" section="S3" start="3047,3168" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pneumocystis carinii infection" meddra_llt_id="10035658" meddra_pt="Pneumocystis jirovecii infection" meddra_pt_id="10073756" />
    </Mention>
    <Mention id="M303" len="10,10" reason="class_effect" section="S3" start="3047,3184" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Toxoplasma gondii infection" meddra_llt_id="10054155" meddra_pt="Toxoplasmosis" meddra_pt_id="10044272" />
    </Mention>
    <Mention id="M249" len="16" reason="preexisting_condition_or_risk_factor" section="S3" start="3223" type="Not_AE_Candidate">
      <Normalization meddra_llt="Amebiasis" meddra_llt_id="10001916" meddra_pt="Amoebiasis" meddra_pt_id="10001980" />
    </Mention>
    <Mention id="M250" len="16" reason="preexisting_condition_or_risk_factor" section="S3" start="3243" type="Not_AE_Candidate">
      <Normalization meddra_llt="Amebiasis" meddra_llt_id="10001916" meddra_pt="Amoebiasis" meddra_pt_id="10001980" />
    </Mention>
    <Mention id="M246" len="8" reason="preexisting_condition_or_risk_factor" section="S3" start="3395" type="Not_AE_Candidate">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M238" len="38" reason="preexisting_condition_or_risk_factor" section="S3" start="3501" type="Not_AE_Candidate">
      <Normalization meddra_llt="Strongyloides stercoralis infection" meddra_llt_id="10042253" meddra_pt="Strongyloidiasis" meddra_pt_id="10042254" />
    </Mention>
    <Mention id="M293" len="40" reason="class_effect" section="S3" start="3559" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Immunosuppression" meddra_llt_id="10062016" meddra_pt="Immunosuppression" meddra_pt_id="10062016" />
    </Mention>
    <Mention id="M294" len="28" reason="class_effect" section="S3" start="3612" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Strongylodiasis hyperinfection" meddra_llt_id="10080246" meddra_pt="Strongyloidiasis" meddra_pt_id="10042254" />
    </Mention>
    <Mention id="M269" len="13" reason="manifestation_or_complication" section="S3" start="3721" type="NonOSE_AE">
      <Normalization meddra_llt="Enterocolitis" meddra_llt_id="10014893" meddra_pt="Enterocolitis" meddra_pt_id="10014893" />
    </Mention>
    <Mention id="M261" len="5" reason="general_term" section="S3" start="3751" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M270" len="24" reason="manifestation_or_complication" section="S3" start="3757" type="NonOSE_AE">
      <Normalization meddra_llt="Septicemia gram-negative" meddra_llt_id="10054611" meddra_pt="Bacterial sepsis" meddra_pt_id="10053840" />
    </Mention>
    <Mention id="M239" len="16" reason="preexisting_condition_or_risk_factor" section="S3" start="3823" type="Not_AE_Candidate">
      <Normalization meddra_llt="Cerebral malaria" meddra_llt_id="10063094" meddra_pt="Cerebral malaria" meddra_pt_id="10063094" />
    </Mention>
    <Mention id="M277" len="12" reason="general_term" section="S3" start="3844" type="NonOSE_AE">
      <Normalization meddra_llt="Tuberculosis" meddra_llt_id="10044755" meddra_pt="Tuberculosis" meddra_pt_id="10044755" />
    </Mention>
    <Mention id="M248" len="19" reason="indication" section="S3" start="3890" type="Not_AE_Candidate">
      <Normalization meddra_llt="Active tuberculosis" meddra_llt_id="10071157" meddra_pt="Tuberculosis" meddra_pt_id="10044755" />
    </Mention>
    <Mention id="M247" len="11,12" reason="indication" section="S3" start="3949,3977" type="Not_AE_Candidate">
      <Normalization meddra_llt="Tuberculosis" meddra_llt_id="10044755" meddra_pt="Tuberculosis" meddra_pt_id="10044755" />
    </Mention>
    <Mention id="M240" len="25" reason="indication" section="S3" start="3964" type="Not_AE_Candidate">
      <Normalization meddra_llt="Disseminated tuberculosis" meddra_llt_id="10013453" meddra_pt="Disseminated tuberculosis" meddra_pt_id="10013453" />
    </Mention>
    <Mention id="M262" len="15" reason="AE_only_as_instruction" section="S3" start="4095" type="NonOSE_AE">
      <Normalization meddra_llt="Antibiotic therapy" meddra_llt_id="10067768" meddra_pt="Antibiotic therapy" meddra_pt_id="10067768" />
    </Mention>
    <Mention id="M241" len="19" reason="indication" section="S3" start="4172" type="Not_AE_Candidate">
      <Normalization meddra_llt="Latent tuberculosis" meddra_llt_id="10065048" meddra_pt="Latent tuberculosis" meddra_pt_id="10065048" />
    </Mention>
    <Mention id="M242" len="21" reason="indication" section="S3" start="4195" type="Not_AE_Candidate">
      <Normalization meddra_llt="Tuberculin test positive" meddra_llt_id="10044728" meddra_pt="Tuberculin test positive" meddra_pt_id="10044728" />
    </Mention>
    <Mention id="M263" len="17" reason="AE_only_as_instruction" section="S3" start="4491" type="NonOSE_AE">
      <Normalization meddra_llt="Immunosuppression" meddra_llt_id="10062016" meddra_pt="Immunosuppression" meddra_pt_id="10062016" />
    </Mention>
    <Mention id="M243" len="17" reason="preexisting_condition_or_risk_factor" section="S3" start="4770" type="Not_AE_Candidate">
      <Normalization meddra_llt="Disease Addison's" meddra_llt_id="10013096" meddra_pt="Addison's disease" meddra_pt_id="10001130" />
    </Mention>
    <Mention id="M271" len="16" reason="general_term" section="S3" start="4792" type="NonOSE_AE">
      <Normalization meddra_llt="Infection viral" meddra_llt_id="10021876" meddra_pt="Viral infection" meddra_pt_id="10047461" />
      <Normalization meddra_pt="Infection reactivation" meddra_pt_id="10070891" />
    </Mention>
    <Mention id="M272" len="10" reason="AE_only_as_instruction" section="S3" start="4812" type="NonOSE_AE">
      <Normalization meddra_llt="Chickenpox" meddra_llt_id="10008505" meddra_pt="Varicella" meddra_pt_id="10046980" />
    </Mention>
    <Mention id="M273" len="7" reason="AE_only_as_instruction" section="S3" start="4827" type="NonOSE_AE">
      <Normalization meddra_llt="Measles" meddra_llt_id="10027011" meddra_pt="Measles" meddra_pt_id="10027011" />
    </Mention>
    <Mention id="M264" len="5" reason="general_term" section="S3" start="4867" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M266" len="10" reason="AE_only_as_instruction" section="S3" start="5174" type="NonOSE_AE">
      <Normalization meddra_llt="Chickenpox" meddra_llt_id="10008505" meddra_pt="Varicella" meddra_pt_id="10046980" />
    </Mention>
    <Mention id="M265" len="38" reason="AE_only_as_instruction" section="S3" start="5203" type="NonOSE_AE">
      <Normalization meddra_llt="Immunoglobulin therapy" meddra_llt_id="10069534" meddra_pt="Immunoglobulin therapy" meddra_pt_id="10069534" />
      <Normalization meddra_pt="Drug therapy" meddra_pt_id="10063370" />
    </Mention>
    <Mention id="M274" len="7" reason="AE_only_as_instruction" section="S3" start="5275" type="NonOSE_AE">
      <Normalization meddra_llt="Measles" meddra_llt_id="10027011" meddra_pt="Measles" meddra_pt_id="10027011" />
    </Mention>
    <Mention id="M267" len="10" reason="manifestation_or_complication" section="S3" start="5434" type="NonOSE_AE">
      <Normalization meddra_llt="Chickenpox" meddra_llt_id="10008505" meddra_pt="Varicella" meddra_pt_id="10046980" />
    </Mention>
    <Mention id="M295" len="31" reason="class_effect" section="S3" start="5563" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Posterior subcapsular cataract" meddra_llt_id="10036364" meddra_pt="Cataract subcapsular" meddra_pt_id="10007764" />
    </Mention>
    <Mention id="M296" len="8" reason="class_effect" section="S3" start="5596" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Glaucoma" meddra_llt_id="10018304" meddra_pt="Glaucoma" meddra_pt_id="10018304" />
    </Mention>
    <Mention id="M268" len="26" reason="manifestation_or_complication" section="S3" start="5619" type="NonOSE_AE">
      <Normalization meddra_llt="Optic nerve damage" meddra_llt_id="10075452" meddra_pt="Optic nerve injury" meddra_pt_id="10030938" />
    </Mention>
    <Mention id="M304" len="17" reason="class_effect" section="S3" start="5694" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Eye infection" meddra_llt_id="10015929" meddra_pt="Eye infection" meddra_pt_id="10015929" />
    </Mention>
    <Mention id="M305" len="33" reason="class_effect" section="S3" start="5694" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ocular infection bacillary" meddra_llt_id="10030044" meddra_pt="Eye infection bacterial" meddra_pt_id="10015930" />
    </Mention>
    <Mention id="M306" len="52" reason="class_effect" section="S3" start="5694" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Eye infection viral" meddra_llt_id="10015940" meddra_pt="Eye infection viral" meddra_pt_id="10015940" />
    </Mention>
    <Mention id="M307" len="40" reason="class_effect" section="S3" start="5694" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Eye fungal infection" meddra_llt_id="10015925" meddra_pt="Eye infection fungal" meddra_pt_id="10015933" />
    </Mention>
    <Mention id="M244" len="14" reason="preexisting_condition_or_risk_factor" section="S3" start="5819" type="Not_AE_Candidate">
      <Normalization meddra_llt="Neuritis optic" meddra_llt_id="10029247" meddra_pt="Optic neuritis" meddra_pt_id="10030942" />
    </Mention>
    <Mention id="M245" len="21" reason="preexisting_condition_or_risk_factor" section="S3" start="5936" type="Not_AE_Candidate">
      <Normalization meddra_llt="Herpes simplex iridocyclitis" meddra_llt_id="10019954" meddra_pt="Ophthalmic herpes simplex" meddra_pt_id="10073938" />
    </Mention>
  </Mentions>
</GoldLabel>